Nivolumab (Opdivo) plus ipilumumab (Yervoy) is the established first-line treatment for advanced renal cell carcinoma (RCC), but optimal duration of nivolumab and sequencing for ipilumumab remains unclear. Results from the response-based phase II OMNIVORE study, presented during the 2020 ASCO Virtual Scientific Program, demonstrated that delayed treatment with ipilumumab is insufficient to achieve a response in patients with RCC.
In an interview with CancerNetwork, Rana R. McKay, MD of the University of California San Diego discusses the impact of these findings, and what it may mean for practicing clinicians.
Transcription:
So, with regards to the impact of this study, you know, many individuals, out in clinical practice in the community are faced with patients before them and are constantly asking the question of balancing risk and toxicity. Does everybody need to get…
